[go: up one dir, main page]

WO2008112695A3 - Pyrazolo [3,4-d] pyrimidines and 1, 2, 5, 6-tetraaza- as- indacenes as protein kinase inhibitors for cancer treatment - Google Patents

Pyrazolo [3,4-d] pyrimidines and 1, 2, 5, 6-tetraaza- as- indacenes as protein kinase inhibitors for cancer treatment Download PDF

Info

Publication number
WO2008112695A3
WO2008112695A3 PCT/US2008/056523 US2008056523W WO2008112695A3 WO 2008112695 A3 WO2008112695 A3 WO 2008112695A3 US 2008056523 W US2008056523 W US 2008056523W WO 2008112695 A3 WO2008112695 A3 WO 2008112695A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
protein kinase
kinase inhibitors
indacenes
tetraaza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/056523
Other languages
French (fr)
Other versions
WO2008112695A2 (en
Inventor
Pingda Ren
Xia Wang
Yun He
Barun Okram
Xiaodong Wang
Guobao Zhang
Zuosheng Liu
Yi Liu
Pamela A Albaugh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IRM LLC
Original Assignee
IRM LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IRM LLC filed Critical IRM LLC
Publication of WO2008112695A2 publication Critical patent/WO2008112695A2/en
Publication of WO2008112695A3 publication Critical patent/WO2008112695A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, and methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of Alk, Abl, Aurora-A, B-raf, Bcr-Abl, BRK, Blk, Bmx, cKit, c-RAF, cSRC, CSK, FLT1, Fms, Fyn, JAK2, KDR, Lck, Lyn, PDGFRα, PDGFRβ, PKCα, p38 (p38 MAP kinase, SAPK2α), Src, SIK, Syk, Tie2 and TrkB kinases. Formula (I) wherein L is attached at any position on Ring E and is -NR4(CO)CR2)n or - (CO)NR4(CR2)ni X is a bond or C(O); Y is a 5-7 membered carbocyclic ring, aryl, heterocyclic ring or heteroaryl;
PCT/US2008/056523 2007-03-12 2008-03-11 Pyrazolo [3,4-d] pyrimidines and 1, 2, 5, 6-tetraaza- as- indacenes as protein kinase inhibitors for cancer treatment Ceased WO2008112695A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89442007P 2007-03-12 2007-03-12
US60/894,420 2007-03-12

Publications (2)

Publication Number Publication Date
WO2008112695A2 WO2008112695A2 (en) 2008-09-18
WO2008112695A3 true WO2008112695A3 (en) 2008-12-18

Family

ID=39758477

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/056523 Ceased WO2008112695A2 (en) 2007-03-12 2008-03-11 Pyrazolo [3,4-d] pyrimidines and 1, 2, 5, 6-tetraaza- as- indacenes as protein kinase inhibitors for cancer treatment

Country Status (1)

Country Link
WO (1) WO2008112695A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12195467B2 (en) 2018-07-26 2025-01-14 Jbklab Co., Ltd. Compound having TrkA inhibitory activity and pharmaceutical composition, for preventing or alleviating pain, containing same as active ingredient

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200940540A (en) 2008-02-29 2009-10-01 Array Biopharma Inc RAF inhibitor compounds and methods of use thereof
EP2265610B1 (en) 2008-02-29 2012-12-12 Array Biopharma, Inc. Pyrazole [3, 4-b]pyridine raf inhibitors
EP3031324A3 (en) 2008-06-10 2016-09-07 AbbVie Inc. Tricyclic kinase inhibitors
TW201103904A (en) * 2009-06-11 2011-02-01 Hoffmann La Roche Janus kinase inhibitor compounds and methods
US8785639B2 (en) 2009-12-01 2014-07-22 Abbvie Inc. Substituted dihydropyrazolo[3,4-D]pyrrolo[2,3-B]pyridines and methods of use thereof
CN102711476B (en) 2009-12-01 2014-12-03 Abbvie公司 Novel tricyclic compounds
MA37519B1 (en) 2012-05-15 2017-03-31 Novartis Ag Compounds and compositions for inhibiting the activity of abl1, abl2 and bcr-abl1
AU2013261130A1 (en) 2012-05-15 2014-10-23 Novartis Ag Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
WO2013171641A1 (en) 2012-05-15 2013-11-21 Novartis Ag Compounds and compositions for inhibiting the activity of abl1, abl2 and bcr-abl1
CA2871332A1 (en) 2012-05-15 2013-11-21 Novartis Ag Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
EP2689778A1 (en) * 2012-07-27 2014-01-29 Pierre Fabre Medicament Derivatives of azaindoles or diazaindoles for treating pain
EP2689779A1 (en) 2012-07-27 2014-01-29 Pierre Fabre Medicament Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing trk
RS57117B1 (en) * 2012-12-21 2018-06-29 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
WO2015031562A1 (en) * 2013-08-29 2015-03-05 Bristol-Myers Squibb Company PROCESS FOR THE PREPARATION OF N,N-DICYCLOPROPYL-4-(1,5-DIMETHYL-1H-PYRAZOL-3-YLAMINO)-6-ETHYL-1-METHYL-1,6-DIHYDROIMIDAZO[4,5-d]PYRROLO[2,3-b]PYRIDINE-7-CARBOXAMIDE
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
CN116270646A (en) 2015-10-16 2023-06-23 艾伯维公司 Process for preparing imidazo[1,2-a]pyrrolo[2,3-e]pyrazines and their solid state forms
US11773106B2 (en) 2015-10-16 2023-10-03 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
KR102128018B1 (en) 2017-05-12 2020-06-30 한국화학연구원 pyrazolopyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer, autoimmune disease and brain disease containing the same as an active ingredient
WO2018208132A1 (en) * 2017-05-12 2018-11-15 Korea Research Institute Of Chemical Technology Pyrazolopyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer, autoimmune disease and brain disease containing the same as an active ingredient
AU2019264078A1 (en) * 2018-05-02 2020-12-17 Jw Pharmaceutical Corporation Novel heterocycle derivative
CA3117510A1 (en) 2018-10-25 2020-04-30 Merck Patent Gmbh 5-azaindazole derivatives as adenosine receptor antagonists
IL282527B2 (en) 2018-10-25 2025-03-01 Merck Patent Gmbh Azaindazole-5 derivatives and their use
EP3990458A4 (en) * 2019-06-25 2025-01-08 Sinopsee Therapeutics COMPOUNDS FOR THE TREATMENT OF CANCER
CN115605460A (en) 2020-04-29 2023-01-13 普莱希科公司（Us） Synthesis of Heterocyclic Compounds
TW202313053A (en) * 2021-07-30 2023-04-01 瑞士商艾克泰聯製藥有限公司 Pyrazolopyrimidines and their uses as pdgfr inhibitors
WO2024104968A1 (en) * 2022-11-14 2024-05-23 Actelion Pharmaceuticals Ltd Pyrazolopyrrolopyridazines and their uses as pdgfr inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005085248A1 (en) * 2004-02-27 2005-09-15 F.Hoffmann-La Roche Ag Heteroaryl-fused pyrazolo derivatives
WO2007024680A1 (en) * 2005-08-22 2007-03-01 Amgen Inc. Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005085248A1 (en) * 2004-02-27 2005-09-15 F.Hoffmann-La Roche Ag Heteroaryl-fused pyrazolo derivatives
WO2007024680A1 (en) * 2005-08-22 2007-03-01 Amgen Inc. Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
P. TRAXLER, G. BOLD, J. FREI, M. LANG, N. LYDON, H. METT, E. BUCHDUNGER, T. MEYER, M. MÜLLER, P. FURET: "Use of a Pharmacophore Model for the Design of EGF-R Tyrosine Kinase Inhibitors: 4-(Phenylamino)pyrazolo[3,4-d]pyrimidines", JOURNAL OF MEDICINAL CHEMISTRY, vol. 40, 1997, pages 3601-3616, XP002497479 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12195467B2 (en) 2018-07-26 2025-01-14 Jbklab Co., Ltd. Compound having TrkA inhibitory activity and pharmaceutical composition, for preventing or alleviating pain, containing same as active ingredient

Also Published As

Publication number Publication date
WO2008112695A2 (en) 2008-09-18

Similar Documents

Publication Publication Date Title
WO2008112695A3 (en) Pyrazolo [3,4-d] pyrimidines and 1, 2, 5, 6-tetraaza- as- indacenes as protein kinase inhibitors for cancer treatment
MX2009013782A (en) Protein kinase inhibitors and methods for using thereof.
MX2010002005A (en) 2-heteroarylamino-pyrimidine derivatives as kinase inhibitors.
MX2009010728A (en) Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors.
ATE499374T1 (en) COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
WO2006124863A3 (en) Pyrrolopyridine derivatives as protein kinase inhibitors
MX2008002165A (en) Compounds and compositions as protein kinase inhibitors.
NO20063758L (en) Pyrazolo [1,5-A] pyrimidin-7-yl-amine derivatives for use in the treatment of protein kinase dependent diseases
WO2010009342A3 (en) Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
WO2009007390A3 (en) 2-pyraz inylbenz imidazole derivatives as receptor tyrosine kinase inhibitors
WO2006081172A3 (en) Compounds and compositions as protein kinase inhibitors
CL2008001932A1 (en) Compounds derived from 6-cycloamino-3- (pyridin-4-yl) imidazo [1,2-b] pyridazine, cq1epsilon and / or ck1delta inhibitors; preparation procedure; pharmaceutical composition comprising them; and use in the treatment of sleep disorders, circadian rhythm disorder, cancer, and Alzheimer's disease.
TNSN06053A1 (en) 6-substituted anilino purines as rtk inhibitors
EA201000003A1 (en) PROTEINKINAZ INHIBITORS AND METHODS OF THEIR APPLICATION
EP2526933A3 (en) Inhibitors of bruton's tyrosine kinase
WO2009007748A3 (en) Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
MX2009003456A (en) Compounds and compositions as protein kinase inhibitors.
TW200745123A (en) Pyrazolopyrimidines as protein kinase inhibitors
WO2008078100A3 (en) Tricyclic amine derivatives as protein tyrosine kinase inhibitors
WO2008121687A3 (en) Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors
GEP20125658B (en) Imidazotriazines and imidazo pyrimidines as kinase inhibitors
MX2010002004A (en) 5- (4- (haloalkoxy) phenyl) pyrimidine-2-amine compounds and compositions as kinase inhibitors.
TW200621762A (en) Novel compounds
TW200602328A (en) Quinazoline derivatives
TW200628452A (en) Substituted 2-anilinopyrimidines as cell-cycle-kinase or receptor-tyrosine-kinase inhibitors, their production and use as pharmaceutical agents

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08731903

Country of ref document: EP

Kind code of ref document: A2